<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04534699</url>
  </required_header>
  <id_info>
    <org_study_id>KBP5074-1-006</org_study_id>
    <nct_id>NCT04534699</nct_id>
  </id_info>
  <brief_title>Pharmacokinetics of KBP-5074 in Patients With Moderate Hepatic Impairment</brief_title>
  <official_title>A Phase 1, Open Label, Nonrandomized, Single-dose Study to Investigate the Safety, Tolerability, and Pharmacokinetics of KBP-5074 in Subjects With Moderate Hepatic Impairment Compared to Subjects With Normal Hepatic Function</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>KBP Biosciences</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Covance</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>KBP Biosciences</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This multiple-center, nonrandomized, open label, parallel group, single dose study will be&#xD;
      conducted in male and female subjects with normal hepatic function or moderate (Child-Pugh&#xD;
      Class B) hepatic impairment to evaluate the effect of hepatic impairment on the&#xD;
      pharmacokinetics (PK) of KBP-5074.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 27, 2020</start_date>
  <completion_date type="Actual">November 19, 2020</completion_date>
  <primary_completion_date type="Actual">November 19, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacokinetic Parameter: Maximum observed concentration (Cmax)</measure>
    <time_frame>0.5, 1, 2, 4, 6, 8, 12, 24, 48, 72, 96, 120, 144, 168, 192, 216, 240, and 264 hours postdose.</time_frame>
    <description>Maximum observed concentration (Cmax) - Plasma</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetic Paramete: Area under the concentration-time curve from time 0 to infinity (AUC0-∞)</measure>
    <time_frame>0.5, 1, 2, 4, 6, 8, 12, 24, 48, 72, 96, 120, 144, 168, 192, 216, 240, and 264 hours postdose.</time_frame>
    <description>Area under the concentration-time curve from time 0 to infinity (AUC0-∞) - Plasma</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetic Parameter: Area under the plasma concentration time curve from time zero to time of last quantifiable concentration (AUC0-tlast)</measure>
    <time_frame>0.5, 1, 2, 4, 6, 8, 12, 24, 48, 72, 96, 120, 144, 168, 192, 216, 240, and 264 hours postdose.</time_frame>
    <description>Area under the plasma concentration time curve from time zero to time of last quantifiable concentration (AUC0-tlast) - Plasma</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetic Parameter: Time of the maximum observed concentration (tmax)</measure>
    <time_frame>0.5, 1, 2, 4, 6, 8, 12, 24, 48, 72, 96, 120, 144, 168, 192, 216, 240, and 264 hours postdose.</time_frame>
    <description>Time of the maximum observed concentration (tmax) - Plasma</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety of KBP-5074 by assessing the number of adverse events, laboratory abnormalities, ECGs, vital signs and physical examinations</measure>
    <time_frame>Up to 12 days</time_frame>
    <description>Incidence of severity of AEs, laboratory abnormalities (based on hematology, clinical chemistry, and urinalysis test results), ECGs, vital signs, and physical examinations</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">12</enrollment>
  <condition>Moderate Hepatic Impairment</condition>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Hepatic Impaired</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>KBP-5074 0.5mg tablet orally, Single dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Matched-control Healthy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>KBP-5074 0.5mg tablet orally, Single dose</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>KBP-5074</intervention_name>
    <description>KBP-5074 tablet</description>
    <arm_group_label>Hepatic Impaired</arm_group_label>
    <arm_group_label>Matched-control Healthy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:&#xD;
&#xD;
          1. Males or females, of any race, between 18 and 80 years of age, inclusive, at&#xD;
             screening.&#xD;
&#xD;
          2. Body mass index between 18.0 and 40.0 kg/m2, inclusive, at screening.&#xD;
&#xD;
          3. Subjects with normal hepatic function must be in good health.&#xD;
&#xD;
          4. Subjects must meet the criteria for moderate hepatic impairment based on Child Pugh B.&#xD;
&#xD;
        Key Exclusion Criteria:&#xD;
&#xD;
          1. Significant history or clinical manifestation of any medical history, as determined by&#xD;
             the investigator not appropriate to participate in this study.&#xD;
&#xD;
          2. Positive serology test results for hepatitis B surface antigen and/or human&#xD;
             immunodeficiency virus 1/2.&#xD;
&#xD;
          3. Participation in a clinical study involving administration of an investigational drug&#xD;
             (new chemical entity) in the past 30 days or 5 half-lives prior to dosing, whichever&#xD;
             is longer.&#xD;
&#xD;
          4. Use of mineralocorticoids or MRAs (eg, spironolactone or eplenerone) within 90 days&#xD;
             prior to study drug administration, unless deemed acceptable by the medical monitor&#xD;
             and sponsor.&#xD;
&#xD;
          5. Subject has used prescription drugs within 30 days of study drug administration, with&#xD;
             the exception of established therapy for hepatic disease and the treatment of&#xD;
             associated disorders that have been stable for at least 30 days before study drug&#xD;
             administration, as approved by the investigator and in consultation with the medical&#xD;
             monitor.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>James McCabe</last_name>
    <role>Study Director</role>
    <affiliation>KBP Biosciences</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Orlando Clinical Research Center (OCRC)</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32809</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Texas Liver Institute (TLI)</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Trials of Texas (CTT)</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>August 27, 2020</study_first_submitted>
  <study_first_submitted_qc>August 27, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">September 1, 2020</study_first_posted>
  <last_update_submitted>January 7, 2021</last_update_submitted>
  <last_update_submitted_qc>January 7, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hepatic Impairment</keyword>
  <keyword>Moderate Hepatic Impairment</keyword>
  <keyword>Healthy</keyword>
  <keyword>KBP-5074</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

